《全国医保信息平台药品采购年度报告(2026)》于2025年11月14日在江苏苏州发布 1。数据显示,截至2024年,国家谈判纳入的药品累计已达530种 1。报告指出,与2024年相比,84.2%的国谈药品在2025年实现了采购金额和数量的双重增长 1。
具体数据方面,2025年全国医保信息平台药品采购总金额为10462亿元,较2024年增长5% 1。其中,国谈药品采购金额为1725亿元,同比增长48% 1。国家医保局医药价格和招标采购指导中心主任丁一磊表示:“国谈药采购金额增幅几乎是药品整体采购金额增幅的10倍” 1。
On November 14, 2025, the Annual Report on Drug Procurement of the National Healthcare Security Information Platform (2026) was released in Suzhou, Jiangsu Province 1. The report highlights significant growth in the procurement of drugs included in the national medical insurance catalog through negotiations. Compared to 2024 data, 84.2% of these nationally negotiated drugs achieved simultaneous increases in both procurement value and volume in 2025 1. By the end of 2024, the cumulative number of such nationally negotiated drugs had reached 530 varieties 1.
According to the report, the total drug procurement value on the National Healthcare Security Information Platform in 2025 amounted to 104.62 billion yuan, representing a 5% increase over 2024 figures 1. In contrast, the procurement value specifically for nationally negotiated drugs surged by 48% year-on-year to reach 17.25 billion yuan 1. Ding Yilei, Director of the Center for Pharmaceutical Price and Bidding Procurement Guidance at the National Healthcare Security Administration, stated that "the growth rate of procurement value for nationally negotiated drugs is almost ten times that of overall drug procurement" 1. This trend reflects efforts to support the development of innovative drugs while alleviating medication burdens for patients 1.
评论
还没有评论,欢迎留下第一条。